Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
Comment of the Day

April 16 2020

Commentary by Eoin Treacy

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

This article by Adam Feuerstein for statnews.com may be of interest to subscribers. Here is a section:

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment - This article by Adam Feuerstein for statnews.com may be of interest to subscribers. Here is a section:

A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.

The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir. 

“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.

Eoin Treacy's view

One of the biggest challenges with COVID-19 is hospitals had no treatment for it so they were flying blind with how they manage patients with severe symptoms. That has resulted in prolonged stays in hospital which has gummed up the medical systems of a significant number of countries.

Click HERE to subscribe to Fuller Treacy Money Back to top